|
Q2 FY2027
As of Sep 30, 2026
|
Q1 FY2027
As of Jun 30, 2026
|
Q4 FY2026
As of Mar 31, 2026
|
Q3 FY2026
As of Dec 31, 2025
|
Q2 FY2026
As of Sep 30, 2025
|
Q1 FY2026
As of Jun 30, 2025
|
Q4 FY2025
As of Mar 31, 2025
|
Q3 FY2025
As of Dec 31, 2024
|
Q2 FY2025
As of Sep 30, 2024
|
Q1 FY2025
As of Jun 30, 2024
|
Q4 FY2024
As of Mar 31, 2024
|
Q3 FY2024
As of Dec 31, 2023
|
Q2 FY2024
As of Sep 30, 2023
|
Q1 FY2024
As of Jun 30, 2023
|
Q4 FY2023
As of Mar 31, 2023
|
Q3 FY2023
As of Dec 31, 2022
|
Q2 FY2023
As of Sep 30, 2022
|
Q1 FY2023
As of Jun 30, 2022
|
Q4 FY2022
As of Mar 31, 2022
|
Q3 FY2022
As of Dec 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts receivable, net of allowance for expected credit losses of $859 and $1,105, respectively | ||||||||||||||||||||
| Contract assets | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Deferred income taxes, non-current | ||||||||||||||||||||
| Other non-current assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Contract liabilities | ||||||||||||||||||||
| Accrued liabilities | ||||||||||||||||||||
| Operating lease liabilities, current | ||||||||||||||||||||
| Finance lease obligations, current | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Deferred income taxes, non-current | ||||||||||||||||||||
| Operating lease liabilities, non-current | ||||||||||||||||||||
| Debt, non-current | ||||||||||||||||||||
| Other non-current liabilities | ||||||||||||||||||||
| Series A convertible preferred stock, no par value | ||||||||||||||||||||
| Shareholders' equity: | ||||||||||||||||||||
| Common shares, without par value, at $0.30 stated value; 80,000,000 shares authorized; 33,342,288 shares issued; and 28,215,472 and 28,166,478 shares outstanding at September 30, 2026 and March 31, 2026, respectively | ||||||||||||||||||||
| Treasury shares, 5,126,816 and 5,175,810 at September 30, 2026 and March 31, 2026, respectively | ||||||||||||||||||||
| Capital in excess of stated value | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total shareholders' equity | ||||||||||||||||||||
| Total liabilities and shareholders' equity | ||||||||||||||||||||
Loading...
